TN2018000127A1 - 1,3,4-thiadiazole compounds and their use in treating cancer - Google Patents

1,3,4-thiadiazole compounds and their use in treating cancer

Info

Publication number
TN2018000127A1
TN2018000127A1 TNP/2018/000127A TN2018000127A TN2018000127A1 TN 2018000127 A1 TN2018000127 A1 TN 2018000127A1 TN 2018000127 A TN2018000127 A TN 2018000127A TN 2018000127 A1 TN2018000127 A1 TN 2018000127A1
Authority
TN
Tunisia
Prior art keywords
sup
hydrogen
methoxy
treating cancer
thiadiazole compounds
Prior art date
Application number
TNP/2018/000127A
Other languages
English (en)
Inventor
Mark Charles
Maurice Finlay
Johannes Nissink
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of TN2018000127A1 publication Critical patent/TN2018000127A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP/2018/000127A 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer TN2018000127A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260789P 2015-11-30 2015-11-30
PCT/EP2016/079250 WO2017093299A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
TN2018000127A1 true TN2018000127A1 (en) 2019-10-04

Family

ID=57485461

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP/2018/000127A TN2018000127A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Country Status (24)

Country Link
US (3) US10323028B2 (enExample)
EP (1) EP3383873B1 (enExample)
JP (1) JP6999550B2 (enExample)
KR (1) KR20180083942A (enExample)
CN (1) CN108349966B (enExample)
AR (1) AR106874A1 (enExample)
AU (1) AU2016363718B2 (enExample)
BR (1) BR112018010806A2 (enExample)
CA (1) CA3005495C (enExample)
CL (1) CL2018001407A1 (enExample)
CO (1) CO2018006928A2 (enExample)
EA (1) EA201891241A1 (enExample)
ES (1) ES2914333T3 (enExample)
IL (1) IL259510A (enExample)
MX (1) MX2018006532A (enExample)
NI (1) NI201800064A (enExample)
PE (1) PE20181565A1 (enExample)
PH (1) PH12018501131A1 (enExample)
RU (1) RU2018123714A (enExample)
SG (1) SG11201803810XA (enExample)
SV (1) SV2018005702A (enExample)
TN (1) TN2018000127A1 (enExample)
TW (1) TW201733587A (enExample)
WO (1) WO2017093299A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN110741003B (zh) * 2017-06-13 2021-07-23 南京明德新药研发有限公司 作为gls1抑制剂的化合物
ES2939506T3 (es) 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
CN108785305B (zh) * 2011-11-21 2021-10-29 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
HUE056078T2 (hu) * 2012-11-16 2022-01-28 Calithera Biosciences Inc Heterociklusos glutamináz inhibitorok
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
US11753405B2 (en) 2023-09-12
SG11201803810XA (en) 2018-06-28
CL2018001407A1 (es) 2018-10-12
MX2018006532A (es) 2019-05-15
US20170152255A1 (en) 2017-06-01
JP2018535986A (ja) 2018-12-06
PE20181565A1 (es) 2018-10-03
WO2017093299A1 (en) 2017-06-08
CN108349966A (zh) 2018-07-31
BR112018010806A2 (en) 2018-11-27
CA3005495A1 (en) 2017-06-08
EP3383873A1 (en) 2018-10-10
AU2016363718B2 (en) 2019-11-14
CA3005495C (en) 2023-12-12
SV2018005702A (es) 2018-11-27
US10323028B2 (en) 2019-06-18
PH12018501131A1 (en) 2019-01-21
AU2016363718A1 (en) 2018-07-12
US20210246131A1 (en) 2021-08-12
CN108349966B (zh) 2022-02-15
NI201800064A (es) 2018-10-18
JP6999550B2 (ja) 2022-02-10
ES2914333T3 (es) 2022-06-09
TW201733587A (zh) 2017-10-01
RU2018123714A (ru) 2020-01-09
US10981904B2 (en) 2021-04-20
IL259510A (en) 2018-07-31
CO2018006928A2 (es) 2018-10-10
EA201891241A1 (ru) 2019-01-31
KR20180083942A (ko) 2018-07-23
AR106874A1 (es) 2018-02-28
US20190389853A1 (en) 2019-12-26
EP3383873B1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
PH12018501131A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
MY170904A (en) Ret inhibitor
MX367897B (es) Derivados de piridazinona macrociclicos.
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
TN2019000210A1 (en) Antitumoral compounds
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
PH12017500184A1 (en) Dioxolane analogues of uridine for the treatment of cancer
MX2017015257A (es) Cristal de (6s, 9as)-n-bencil-8-({6-[3-(4-etilpiperazin-1-il)azeti din-1-il]piridin-2-il}metil)-6-(2-(fluoruro-4-hidroxibencil)-4,7- dioxo-2-prop-2-en-1-il)hexahidro-2h-pirazino[2,1-c] [1,2,4]triazon-1-(6h)-carboxamida.
MX2020012980A (es) Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina.
PH12018501132A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX389800B (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer
PH12018501133A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
MX2019009356A (es) Sulfinilpiridinas y su uso en el tratamiento del cancer.
MX2021015514A (es) Compuesto heterociclico.
MX2018006374A (es) Compuestos de bis-piridazina y su uso en el tratamiento del cancer.
MX2018004879A (es) Nuevos derivados de piridona y su uso como inhibidores de quinasas.
GEP20227437B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
MX395659B (es) Compuestos triciclicos y su uso en el tratamiento del cancer
EA201991208A1 (ru) Способы лечения множественного остеохондроматоза (мо)